Retevmo (selpercatinib) — Medica
Solid tumors, recurrent, advanced, or metastatic, RET fusion-positive
Initial criteria
- Patient is age ≥ 2 years
- Patient has recurrent, advanced, or metastatic solid tumor
- Tumor is rearranged during transfection (RET) fusion-positive
Approval duration
1 year